We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

30 hedge funds and large institutions have $4.19M invested in Provectus Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,483% more capital inflows, than outflows

Capital inflows: $2.94M | Capital outflows: $186K

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

7% more funds holding

Funds holding: 28 → 30 (+2)

1.61% more ownership

Funds ownership: 0.72% → 2.33% (+1.6%)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
30
Holders Change
+2
Holders Change %
+7.14%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PVCT Hedge Fund Activity: Q3 2014 in Review

30 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q3 2014, worth a combined $4.19M — up 282% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PVCT positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $2.87M. The largest seller was Virtu KCG Holdings, cutting an estimated $72.2K.

  • 30 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q3 2014, up from 28 in Q2 2014.
  • Funds reported $4.19M of Provectus Biopharmaceuticals stock for Q3 2014, up 282% quarter-over-quarter.
  • 6 funds opened new Provectus Biopharmaceuticals positions in Q3 2014 and 4 closed out, a net change of +2 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q3 2014 was Vanguard Group, an estimated $2.87M added.
  • The largest Provectus Biopharmaceuticals seller in Q3 2014 was Virtu KCG Holdings, an estimated $72.2K sold.

Based on aggregated 13F filings for Q3 2014.